secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001746473-24-000169
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pliant Therapeutics Q3 net loss $57.8M; BEACON-IPF enrollment on track for Q1 2025
--------------------------------------------------------------------------------

- Net loss of $57.8M vs $41.5M in Q3 2023; R&D expenses rose to $47.8M on BEACON-IPF trial.
- Cash and investments of $406.0M as of Sept 30, 2024; no revenue reported.
- BEACON-IPF Phase 2b/3 trial enrolling well; full enrollment expected Q1 2025, data mid-2026.
- Phase 1 trial of PLN-101095 in solid tumors dosing third cohort; preliminary data early 2025.
- Gary Palmer appointed SVP of Medical Affairs; brings 25+ years from Bristol Myers Squibb.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000174647324000169/0001746473-24-000169-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000174647324000169/plrx-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001746473-24-000169

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer